Editor’s Note: In today’s issue, we look at the 340B provider community’s comments to CMS. In a future issue, we [...] …
Category: Regulatory
A Japanese drug manufacturer has ended its 340B contract pharmacy restrictions in Maryland and Mississippi in conjunction with new contract [...] …
The 340B program faces unprecedented challenges despite a series of states enacting 340B contract pharmacy access laws, the leader of [...] …
A landmark Supreme Court decision to limit the broad regulatory authority of federal agencies will increase pressure for Congress to [...] …
Dozens of hospitals in Texas and other states have filed suits against Department of Health and Human Services (HHS) Secretary [...] …
The New York Times has sued the federal agency tasked with overseeing the 340B program to force the release of [...] …
The Inflation Reduction Act (IRA) may reduce 340B margins for certain high-cost drugs and drive more transparency into the program, an influential pharmaceutical supply chain analyst who has been a frequent 340B critic told an audience of stakeholders late last
…
Pharmaceutical giant Eli Lilly has significantly escalated its restrictions on access to 340B pricing in the contract pharmacy setting, the [...] …
Drug manufacturer Eli Lilly announced a new round of refunds for Humulin, a brand-name insulin, following a 340B ceiling price [...] …
Fourteen years after the Congressional deadline, the long-anticipated revision to the 340B Administrative Dispute Resolution (ADR) process officially took effect [...] …